PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 801–900 of 1,001
Update on tumor metabolism and patterns of response to immunotherapy
Castello, A., & Lopci, E. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03251-3 · Cited by 11
Recent advances regarding tumor microenvironment and immunotherapy in hepatocellular carcinoma
Qin, W., Cao, Z., Liu, S., & Xu, X.-D. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.04 · Cited by 11
“PD-1, a member of the CD28 superfamily plays a key role in delivering co-inhibitory signals to TCR receptors([115]).”
BackgroundBockhorst, C., Dietrich, J., Vogt, T. J., Stauber, R. H., Strieth, S., Bootz, F., Dietrich, D., & de Vos, L. (2020) · Epigenomics · doi:10.2217/epi-2020-0208 · Cited by 14
Programmed Cell Death-1 Pathway Deficiency Enhances Autoimmunity Leading to Dacryoadenitis of Mice
Sakurai, Y., Usui, Y., Hattori, T., Takeuchi, M., Takayama, K., Karasawa, Y., Nishio, Y., Yamakawa, N., Saitoh, D., Gotô, H., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.02.014 · Cited by 11
Zhang, M., Liu, J., Wang, Y., Wang, P., Morris-Natschke, S. L., & Lee, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116579 · Cited by 11
Essential Role of B7-H1 in Double-Stranded RNA–Induced Augmentation of an Asthma Phenotype in Mice
Matsumoto, K., Kan‐o, K., Tsuda, M., Fukuyama, S., Asai, Y., Matsumoto, T., Moriwaki, A., Matsunaga, Y., Tsutsui, H., Kawai, T., et al. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0450oc · Cited by 11
Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice
Jiang, F., Yoshida, T., Nakaki, F., Terawaki, S., Chikuma, S., Kato, Y., Okazaki, I., Honjo, T., & Okazaki, T. (2009) · International Immunology · doi:10.1093/intimm/dxp020 · Cited by 12
Zhou, H., Wu, H., Zhong, Z., Blasco, P., Zeng, J., Wang, J., Liu, H., & Li, X. (2025) · JACS Au · doi:10.1021/jacsau.5c01181 · Cited by 11
C. tropicalis promotes CRC by down-regulating tumor cell-intrinsic PD-1 receptor via autophagy
Qu, J., Chen, Q., Bing, Z., Shen, S., Hou, Y., Lv, M., & Wang, T. (2023) · Journal of Cancer · doi:10.7150/jca.79664 · Cited by 10
“As one of the crucial immune checkpoint molecules, PD-1 belongs to the CD28/CTLA-4 family [6].”
BackgroundXu, X., Luo, S., Zhao, X., Tang, B., Zhang, E., Liu, J., & Duan, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130921 · Cited by 11
Zhou, L., Wan, Y., Zhang, L., Meng, H., Yuan, L., Zhou, S., Cheng, W., & Jiang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116733 · Cited by 11
Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy
Eckert, T., Zobaer, M. S., Boulos, J., Alexander-Bryant, A. A., Baker, T. G., Rivers, C., Das, A., Vandergrift, W. A., Santos, J. L. M., Zukas, A. M., et al. (2025) · Cancers · doi:10.3390/cancers17030462 · Cited by 13
“First discovered Ishida et al., the PD-1/PD-L1 pathway has long been analyzed and targeted for neoplastic pathologies [23–25].”
New Systemic Therapies for Advanced Hepatocellular Carcinoma
Kim, D. Y. (2019) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2019.73.1.10 · Cited by 10
Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer
Grundy, M., Coussios, C. C., & Carlisle, R. C. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1167036 · Cited by 11
Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
Inaba, H., Ariyasu, H., Okuhira, H., Yamamoto, Y., Akamatsu, H., Katsuda, M., Jinnin, M., Hara, I., & Akamizu, T. (2018) · Trends in Immunotherapy · doi:10.24294/ti.v2.i2.606 · Cited by 10
“CD4+Th1-T-cells activate CD8+ T-cells, and CD4+Th2-Tcells stimulate antibody production.”
BackgroundInfluentialHammond, S., Thomson, P., Ogese, M. O., & Naisbitt, D. J. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00327 · Cited by 12
“Built‐in” PD‐1 blocker to rescue NK‐92 activity from PD‐L1–mediated tumor escape mechanisms
Mensali, N., Dillard, P., Fayzullin, A., Köksal, H., Gaudernack, G., Kvalheim, G., Inderberg, E. M., & Wälchli, S. (2021) · The FASEB Journal · doi:10.1096/fj.202100025r · Cited by 10
Jung, C.-J., Yang, H. J., Bang, S., Lee, W. J., Won, C. H., Lee, M.-W., Song, Y., & Chang, S. E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215200 · Cited by 10
Huang, Z., Jin, Y., Xu, C., Chen, L., Shen, X., Li, B., Chen, H., & Li, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14285 · Cited by 9
“and the guidelines of pembrolizumab treatment and separated into two classifications: negative (CPS < 10) and positive expression (CPS ≥ 10).(9,10,31) Patients without sufficient viable tumor cells (<100) were excluded.”
BackgroundImmunobiology of β-Cell Destruction
Torre, D. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_16 · Cited by 15
Update on the challenges and recent advances in cancer immunotherapy
Baronzio, G., Parmar, G., Ballerini, M., Mikhail, K., Valter, C., Shubina, I. Z., & Giuli, S. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s30818 · Cited by 10
“These receptors are not only expressed on MDSC cells and T reg 116 but are also overexpressed in a variety of human cancers including lung, ovarian, skin, colon, esophagus, renal, stomach, and breast.(116,117) Another humanized mAb, BMS-936558 (immunoglobulin 4; BristolMyers Squibb), has generated interesting, albeit…”
Ma, H., Mao, G., Zhang, G., & Huang, H. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1341521 · Cited by 10
“Many researches have demonstrated that the binding of PD-1 with PD-L1 andPD-L2 can inhibit T cell receptor-mediated lymphocyte proliferation and cytokine secretion, therefore leading to the suppression of immune responses (Okazaki & Honjo, 2007).”
BackgroundJiang, C., Cai, X., Zhang, H., Xia, X., Zhang, B., & Xia, L. (2017) · Journal of Cancer · doi:10.7150/jca.21414 · Cited by 11
“Programmed death 1 (PD-1) protein is a key immunosuppressive checkpoint receptor expressed in activated T cells [9].”
BackgroundHu, Z., Ma, Y., Shang, Z., Hu, S., Liang, K., Liang, W., Xing, X., Wang, Y., & Du, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.7978 · Cited by 14
“In addition to tumor cells, PD-L1 is also highly expressed on DCs (16-18).”
Nivolumab in squamous cell carcinoma of the head and neck
Specenier, P. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1456337 · Cited by 12
Functional genomics: paving the way for more successful cancer immunotherapy
Ajina, R., Zamalin, D., & Weiner, L. M. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely017 · Cited by 13
“One of the well-studied checkpoint receptor –ligand interactions is that of programmed death-ligand 1 (PD-L1), which interacts with PD-1 expressed by activated T cells [36].”
BackgroundFurukawa, F. (2019) · Trends in Immunotherapy · doi:10.24294/ti.v2.i3.1065 · Cited by 10
“Honjo showed how different strategies for inhibiting the brakes on the immune system could be used in the treatment of cancer[1-5].”
BackgroundOh, K. S., & Mahalingam, M. (2019) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001287 · Cited by 10
Liu, Y., Gao, Y., Hao, H., & Hou, T. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12865 · Cited by 28
The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer
Chen, J., Yi, X.-J., Shan-xia, G., & Sun, J. (2020) · General Physiology and Biophysics · doi:10.4149/gpb_2020011 · Cited by 11
“Programmed death-1 (PD-1) belongs to the CD28 family and tends to be highly expressed on the surfaces of activated T/B lymphocytes and monocytes (Okazaki and Honjo 2007; Keir et al. 2008), while programmed death ligand-1 (PD-L1), which is one of the PD-1 ligands, is a member of the B7 family and can be expressed on th…”
BackgroundAhn, H., Lee, H. J., Lee, J., Cho, H. D., Oh, M., Son, J. W., & Jang, S. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153188 · Cited by 14
Sajiki, Y., Konnai, S., Okagawa, T., Maekawa, N., Nakamura, H., Kato, Y., Suzuki, Y., Murata, S., & Ohashi, K. (2020) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2020.103847 · Cited by 10
“PD-1 is an immunoinhibitory receptor expressed on T cells, and its upregulation plays a key role in T-cell exhaustion via the interaction with its ligand PD-L1 (Okazaki and Honjo, 2007).”
BackgroundSaito, Y., Fujiwara, Y., Miyamoto, Y., Ohnishi, K., Nakashima, Y., Tabata, Y., Baba, H., & Komohara, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.5747 · Cited by 10
Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets
Tariq, N.-U.-A., Vogel, A., McNamara, M. G., & Valle, J. W. (2018) · Oncology Research and Treatment · doi:10.1159/000488997 · Cited by 10
The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer
Mandal, S. K., Yadav, P., & Sheth, R. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116237 · Cited by 11
“It is characterized predominantly by the presence of immunosuppressive cells such as Kupffer cells, tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), along with their signaling pathways [5,6].”
BackgroundDan, A., Aricak, O., Rounis, K., Montero, Á., Guijarro, R., Ekman, S., Ortiz‐Villalón, C., & Petris, L. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414900 · Cited by 12
Kitazawa, R., & Kitazawa, S. (2025) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.24-00056ep · Cited by 12
“We suggest that a shared underlying mechanism, specifically the rapid decline of programmed cell death 1 (PD-1)-ligand 1 (PD-L1) [5, 29], could potentially explain both conditions.”
Sinnadurai, M., & McDonald, K. L. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2390-3 · Cited by 9
“1 3 In humans, polymorphisms in the Pdcd1 gene has been associated with autoimmune diseases, such as systemic lupus erythematosus (SLE), Graves disease, type 1 diabetes and MS [35].”
BackgroundUnraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity
Qin, X., Denton, W. D., Huiting, L. N., Smith, K. S., & Feng, H. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1784085 · Cited by 10
“With improved understanding of how ERAD regulates proteins relevant to immune checkpoints, such as PD-L1, a more effective combination therapy could be designed.”
BackgroundInfluentialDimerization of Transmembrane Proteins in Cancer Immunotherapy
Li, L., & Li, J. (2023) · Membranes · doi:10.3390/membranes13040393 · Cited by 12
“PD-1 is also expressed in other immune cells, such as macrophages and B cells [80].”
BackgroundLang, M., Gan, L., Ren, S., Han, R., Ma, X., Li, G., Li, H., Zhang, T., Wu, Q., Cui, Y., et al. (2023) · PubMed Central · Cited by 16
Biagi, E., Marin, V., Attianese, G. M. P. G., Pizzitola, I., Tettamanti, S., Cribioli, E., & Biondi, A. (2011) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-37-46 · Cited by 8
“Phase I studies have been performed with CIK cells in various contexts, where no toxicity was observed and several partial responses were detected [20-27].”
BackgroundEnhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies
Amaya, C. N., Wians, F. H., Bryan, B. A., & Torabi, A. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.015 · Cited by 9
Immunoregulatory functions of PD-1/PD-L1 inhibitors and development of resistance to them
Sayapina, M. S. (2017) · Malignant tumours · doi:10.18027/2224-5057-2017-2-94-99 · Cited by 12
Wang, H., Mendez, L. C., Morton, G., Loblaw, A., Mesci, A., Chung, H. T.-K., Chan, S., Huang, X., Downes, M. R., Vesprini, D., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.029 · Cited by 9
Correlation of sPD1 with Procalcitonin and C-Reactive Protein Levels in Patients with Sepsis.
Bakhshiani, Z., Fouladi, S., Mohammadzadeh, S., & Eskandari, N. (2021) · PubMed Central · doi:10.22074/cellj.2021.6941 · Cited by 8
“With knowledge of the mechanism of the immune response in sepsis, several immunosuppression markers are proposed, such as the superfamily B7CD28 called programmed cell death 1 (PD-1) so that PD1 and programmed death ligand-1 (PD-L1) inhibit the function of B and T cells (13, 14).”
BackgroundOkonogi, N., Usui, H., Murata, K., Hori, M., Kurokawa, T., Fujiwara, T., Fujii, Y., Hanawa, M., Kawasaki, Y., Hattori, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056424 · Cited by 9
Park, B. J., Stone, C. A., Dewan, A. K., & Johnson, D. B. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.12.006 · Cited by 11
A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration
Feng, Y., Tao, F., Qiao, H., & Tang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1159725 · Cited by 12
Immunoregulation of hepatitis B virus infection--rationale and clinical application.
Ishikawa, T. (2012) · Institutional Repositories DataBase (IRDB) · doi:10.18999/nagjms.74.3-4.217 · Cited by 10
Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Shin, J. H., Park, H. B., & Choi, K. (2016) · Immune Network · doi:10.4110/in.2016.16.2.134 · Cited by 9
“PD-1 is an inhibitory receptor expressed mainly on activated T cells, B cells and monocytes (7,8).”
BackgroundTargeting Innate Immunity in Glioma Therapy
Gillard, A. G., Shin, D. H., Hampton, L. A., Lopez-Rivas, A. R., Parthasarathy, A., Fueyo-Margareto, J., & Gomez‐Manzano, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020947 · Cited by 11
How, J., Dang, M., Lee, S., Fellman, B. M., Westin, S. N., Sood, A. K., Fleming, N. D., Shafer, A., Yuan, Y., Liu, J., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.022 · Cited by 10
Gong, Y., Liu, Y., Jiang, F., & Wang, X. (2024) · Seminars in Ophthalmology · doi:10.1080/08820538.2024.2433636 · Cited by 9
PD-1IR2 promotes tumor evasion via deregulating CD8+ T cell function
Zang, H., Liu, T., Wang, X., Cheng, S., Zhu, X., Huang, C., Duan, L., Zhao, X., Guo, F., Wang, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010529 · Cited by 8
“3 4 In addition, either PD-L1 or PD-L2 expressed by cancer cells binds to PD-1 on the surface of T cells, thereby inhibiting T cell activation and leading to cancer immune evasion.”
Therapeutic targeting of tumour-associated macrophage receptors
Martins, R. G. A., Tekin, M. M., Cragg, M. S., & Roghanian, A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf009 · Cited by 11
“Shortly after its initial description, several groups made important contributions to the knowledge we have about the engagement of PD-L1 with PD-1 and how it inhibits the proliferation and cytokine production of activated T cells [155–157].”
Hashinokuchi, A., Haratake, N., Takenaka, T., Matsudo, K., Nagano, T., Watanabe, K., Kosai, K., Oku, Y., Ono, Y., Takamori, S., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14599 · Cited by 8
Okonogi, N., Murata, K., Yamada, S., Habu, Y., Hori, M., Kurokawa, T., Inaba, Y., Fujiwara, T., Fujii, Y., Hanawa, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310565 · Cited by 8
“Tumor cells utilize this immune checkpoint pathway to escape immune surveillance [19].”
BackgroundRoy, S., Gupta, A. K., Banerjee, M., Das, P. K., & Ukil, A. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104758 · Cited by 8
Pourali, G., Zafari, N., Velayati, M., Mehrabadi, S., Maftooh, M., Hassanian, S. M., Mobarhan, M. G., Ferns, G. A., Avan, A., & Khazaei, M. (2023) · Current Drug Targets · doi:10.2174/0113894501264450231129042256 · Cited by 10
Modulatory Role of Phytochemicals/Natural Products in Cancer Immunotherapy
Vijayan, Y., Sandhu, J. S., & Harikumar, K. B. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673274796240116105555 · Cited by 9
Lee, E., Jang, J. Y., & Yang, J. (2024) · Cancers · doi:10.3390/cancers16101896 · Cited by 9
Yu, G., Zhang, Z., Eresen, A., Hou, Q., Amirrad, F., Webster, S., Nauli, S. M., Yaghmai, V., & Zhang, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212038 · Cited by 12
Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors
Chovanec, M., Giorgi, U. D., & Mego, M. (2018) · Advances in Urology · doi:10.1155/2018/3718165 · Cited by 9
“PD-1 is a member of the immunoglobulin superfamily and is expressed on double-negative Tcells in thymus and on activated CD4+ T-cells, CD8+ T-cells, natural killer cells, B-cells, and monocytes [29].”
BackgroundNakamura, Y., Kobayashi, T., Nishii, Y., Suzuki, Y., Saiki, H., Ito, K., Watanabe, F., Nishihama, K., Yasuma, T., D’Alessandro‐Gabazza, C. N., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12861 · Cited by 9
Khanova, M., & Grigoryev, E. V. (2019) · Patologiya krovoobrashcheniya i kardiokhirurgiya · doi:10.21688/1681-3472-2019-3-76-83 · Cited by 9
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer
Alexander, M., Ko, B., Lambert, R., Gadgeel, S. M., & Halmos, B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1702526 · Cited by 9
“In order to avoid immune surveillance and facilitate growth, cancer cells have co-opted the PD-1/PD-L1 regulatory mechanism [1].”
BackgroundSukegawa, K., Shitaoka, K., Hamana, H., Kobayashi, E., Miyahara, Y., Fujii, K., Tsuda, K., Saeki, S., Nagata, T., Ozawa, T., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948399 · Cited by 9
Controversies in the Treatment of Peripheral T‐cell Lymphoma
Bachy, E., Broccoli, A., Dearden, C. E., de Leval, L., Gaulard, P., Koch, R., Morschhauser, F., Trümper, L. H. P., & Zinzani, P. L. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000461 · Cited by 10
“The development of checkpoint inhibitors, targeting the interaction of PD-1 and PD-L1/PD-L2 with subsequent repression of T cell activation has revolutionized therapeutic options in multiple malignancies.(98) In PTCL, increased expression of PD-L1 has been described in both malignant and stromal cells across various s…”
BackgroundWang, X., Yuan, T., Yin, N., Ma, X., Yang, Y., Yang, J., Shaukat, A., & Deng, G. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10026 · Cited by 8
Whooley, J., Alazzawi, M., Donlon, N. E., Bolger, J. C., & Robb, W. B. (2021) · Diseases of the Esophagus · doi:10.1093/dote/doab063 · Cited by 21
Niederkorn, J. Y. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-370454-2.00029-6 · Cited by 9
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer
Bleve, S., Cursano, M. C., Casadei, C., Schepisi, G., Menna, C., Urbini, M., Gianni, C., Padova, S. D., Filograna, A., Gallá, V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910087 · Cited by 8
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
Najafi, S., Majidpoor, J., & Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114436 · Cited by 8
Pettinella, F., Lattanzi, C., Donini, M., Caveggion, E., Marini, O., Iannoto, G., Costa, S. E., Zenaro, E., Fortunato, T. M., Gasperini, S., et al. (2023) · Cancers · doi:10.3390/cancers15215285 · Cited by 7
“Over the past decade, ICIs have revolutionized the treatment of NSCLC [8,9].”
BackgroundThe relationship between amniotic epithelial cells and their microenvironment
Kopaczka, K., Skowron, K., Kolanko, E., & Czekaj, P. (2015) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2015.10.004 · Cited by 9
Charlton, J. J., Tsoukatou, D., Mamalaki, C., & Chatzidakis, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119200 · Cited by 9
“PD-1 is a negative co-stimulatory molecule of the CD28/CTLA-4 family which negatively regulates TCR signaling when engaged by one of its ligands, PD-ligand 1 and PD-ligand 2 [13,14].”
BackgroundTumor immune microenvironment is associated with the growth of intracranial germinomas
Nishimoto, M., Ohara, K., Kamamoto, D., Tamura, R., Miwa, T., Yoshida, K., & Sasaki, H. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03355-0 · Cited by 8
Haywood, S., Garioch, J., Ramaiya, A., & Moncrieff, M. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08713-1 · Cited by 15
“The programmed cell death 1 (PD-1) immune inhibitory receptor is present on T- and B-lymphocytes, natural killer cells, and myeloid cells, and PD-L1 is its corresponding ligand expressed on tumor cells, T and B cells, macrophages, and dendritic cells.(19) The PD-1/PD-L1 interaction is a recognized mechanism whereby ma…”
BackgroundWnt signaling inhibits CTL memory programming
Xiao, Z., Sun, Z., Smyth, K., & Li, L. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.008 · Cited by 8
“inhibitory signals during CTL activation (Greenwald et al., 2005; Okazaki and Honjo, 2007; Riley, 2009; Sharpe et al., 2007).”
Asefi, M., Saidijam, M., Rezvani, N., Soltanian, A. R., Khalilian, A., & Mahdavinezhad, A. (2022) · Personalized Medicine · doi:10.2217/pme-2021-0095 · Cited by 7
Sasmal, P., Prabitha, P., Kumar, B. R. P., Swetha, B. R., Babasahib, S. K., & Raghavendra, N. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108036 · Cited by 8
Immune Checkpoint Inhibitors Impact Fertility: A Review
Shabir, I., & Foster, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871340496250130054721 · Cited by 8
Quan, H., Zhou, H., Chen, F., Chen, J., He, Y., Xiao, H., Liu, J., Shi, L., Xie, W., Chen, P., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02462-4 · Cited by 8
“Pro-grammed cell death-1 (PD-1) is a negative regulator of immunity that binds to the programmed cell death ligand-1 (PD-L1) for transduction of inhibitory signals to T cells and induction of immune escape [3, 4].”
Immune therapies for alopecia areata: evidence and new perspectives
Lai, H.-J., Ye, Z., Chen, S., McElwee, K. J., & Guo, H.-W. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2575365 · Cited by 10
“When PD-1 is activated by its ligand PD-L1, it inhibits T cell activation and proliferation, thereby downregulating the T cell-mediated immune response [262].”
Pembrolizumab in the Management of Metastatic Melanoma
Spain, L. A., Younger, E., Hatipoglu, E., & Larkin, J. (2015) · Melanoma Management · doi:10.2217/mmt.15.33 · Cited by 9
Murayama, M. A., Takada, E., Takai, K., Arimitsu, N. N., Shimizu, J., Tomoko, S., & Suzuki, N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0260838 · Cited by 7
“The binding of PD-1 on T cells to PD-L1 and PD-L2 on antigen-presenting cells negatively regulates T cell effector function [3].”
BackgroundBian, J., Niu, Y., Ma, Y., Chen, F., & Ma, N. (2022) · Applied Bionics and Biomechanics · doi:10.1155/2022/8537966 · Cited by 8
“CD28, CTLA-4, and ICOS all share a 21–33% sequence identity with the extracellular domain [10].”
BackgroundInfluentialRetractedQuach, H. T., Hou, Z., Bellis, R. Y., Saini, J. K., Amador-Molina, A., Adusumilli, P. S., & Xiong, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152323 · Cited by 8
“Programmed cell death 1 (PD-1; also known as CD279) [7] – expressed during T-cell activation and maturation – plays a substantial role in maintaining peripheral tolerance [8] and”
BackgroundThe Role of Hypoxia in Brain Tumor Immune Responses
Park, J. H., & Lee, H. K. (2023) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2022.0043 · Cited by 10
“For example, tumor cells downregulate MHC molecules and prime T cells for exhaustion via immune checkpoint molecules such as programmed cell death (PD) 1 and PD-1 ligand (PD-L1) [50,51].”
BackgroundGreppi, M., Obino, V., Goda, R., Rebaudi, F., Carlomagno, S., Chiesa, M. D., Sivori, S., Ubezio, G., Agostini, V. W., Bò, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183215 · Cited by 8
Sun, Z., Liang, X., Zhang, C., Song, S., & Gao, J.-G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1337997 · Cited by 7
“Among the key players in this evasion strategy is PD-1, also known as CD279 (61).”
BackgroundImmunotherapy of Hepatocellular Carcinoma
Sangro, B., Palmer, D. H., & Melero, I. (2014) · Hepatic Oncology · doi:10.2217/hep.14.16 · Cited by 9
Yu, R., He, Z., Lou, Y., Jiang, H., Wu, Y., Liu, Z., Pan, H., & Han, W. (2017) · Oncotarget · doi:10.18632/oncotarget.22082 · Cited by 6
“Programmed cell death-1 (PD-1) is an immunosuppressive receptor of the CD28/CTLA-4 family, which negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase upon interacting with its ligand (PD-L1) [6].”
BackgroundAn optimized protocol for thein vitrogeneration and functional analysis of human PD1/PD-L1 signal
Khedri, M., Abnous, K., Rafatpanah, H., & Ramezani, M. (2017) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2017.1414843 · Cited by 7
“Interaction of PD1 with its ligands including PD-L1 or PD-L2 induces a negative signal into the PD1-expressed cells [2].”
BackgroundLam, S. T., Huang, H., Fang, X., Wang, Z., Hong, H., Ren, Q., Tian, Y., Lin, S., & Lin, T. (2020) · Cancer Management and Research · doi:10.2147/cmar.s244176 · Cited by 8
Wu, J., Sun, Y., Li, J., Ai, M., You, L., Shi, J., & Yu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763886 · Cited by 8
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors
Zhao, S., Qiu, Y., Yuan, M., & Wang, Z. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03644-2 · Cited by 8
“PD-1 is highly expressed on the surface of activated T cells [21], while PD-L1 is overexpressed on the surface of tumor cells.”
T-cell Inhibitors: A Bench-to-Bedside Review
Das, S., Ariizumi, K., & Cruz, P. D. (2012) · Dermatitis · doi:10.1097/der.0b013e31826e43ed · Cited by 9
“Programmed death 1Ydeficient mice can develop an SLE-like phenotype and fatal autoimmune cardiomyopathy.(5,17,44) TIM-3/TIM-3L may also play a role in SLE pathogenesis via Tregs.”
BackgroundImmune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy.
Hatae, R., & Chamoto, K. (2016) · PubMed · doi:10.11406/rinketsu.57.2224 · Cited by 9
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.